- Published on
Click here to start customizing
- Published on
Oncology- Chemotherapeutic Dose Intensification in Oncology
This guide summarizes the provided text on dose intensification in cancer treatment, focusing on key concepts and clinical applications.
I. Dose-Response and Dose Intensification:
HDC has shown efficacy in various cancers, although the success rates vary:
This guide summarizes the provided text on dose intensification in cancer treatment, focusing on key concepts and clinical applications.
I. Dose-Response and Dose Intensification:
- Central Idea: Cancer cell drug resistance is often relative, not absolute. Therefore, arbitrarily reducing drug doses should be avoided.
- Clinical Implications: To overcome resistance and achieve better outcomes, dose intensification strategies are employed. This might necessitate using supportive care (e.g., prophylactic antibiotics, hematopoietic growth factors) to mitigate the increased toxicity associated with higher doses. The goal is to deliver potentially curative chemotherapy on a timely basis, even if it means managing side effects.
- Limitations of Conventional Dose Escalation: Increasing chemotherapy doses within a conventional range has inconsistently improved response rates and minimally impacted survival, often with increased toxicity.
- Hematopoietic Support: Advances in hematopoietic support (using autologous bone marrow or cytokine-mobilized peripheral blood progenitors – PBPs) have enabled the use of HDC. These methods rescue the bone marrow from the myelosuppressive effects of the high-dose chemotherapy.
- PBP Autografting: Superior to marrow autografting, leading to shorter periods of neutropenia and thrombocytopenia, reduced mortality, and reduced morbidity. This involves harvesting PBPs from the peripheral blood via leucopheresis, then re-infusing them after HDC.
- Timing and Administration of HDC: Primarily used as consolidation therapy after conventional chemotherapy. Less commonly used as first-line (initial) treatment. Can be given in single or multiple cycles.
HDC has shown efficacy in various cancers, although the success rates vary:
- Relapsed aggressive lymphoma: Proven salvage therapy (treatment after other therapies have failed).
- Refractory lymphoma: Lower remission rates (around 10%).
- Poor prognosis Non-Hodgkin lymphoma (NHL): May be used as a first-line treatment.
- Multiple myeloma: May be used as a first-line treatment.
- Relapsed/refractory Hodgkin's disease: May be used as a first-line treatment.
- Acute leukemia: Especially relevant when a bone marrow donor is unavailable.
- Metastatic testicular germ cell tumors: In cases of relapse after the second remission.
- Alternative to HDC: This strategy shortens the interval between cycles of conventional chemotherapy, typically supported by granulocyte colony-stimulating factor (G-CSF).
- Status: Shows promise (particularly in adjuvant therapy for high-risk breast cancer), but remains experimental.
- Myelosuppression: Suppression of bone marrow function, leading to reduced blood cell production (neutropenia, thrombocytopenia).
- Autografting: Transplantation of the patient's own bone marrow or PBPs.
- Leucopheresis: Procedure to separate white blood cells (including PBPs) from blood.
- Neutropenia: Low neutrophil count (type of white blood cell).
- Thrombocytopenia: Low platelet count.
- Adjuvant chemotherapy: Chemotherapy given after the primary treatment (surgery, radiation) to reduce the risk of recurrence.
- Consolidation chemotherapy: Intensive chemotherapy given after achieving remission to further reduce the risk of recurrence.
- Salvage therapy: Treatment given after initial treatment has failed.
- Refractory: Resistant to treatment.
